AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Portal Hypertension - Pipeline Insight, 2019 by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

February 15, 2019

DUBLIN--(BUSINESS WIRE)--Feb 15, 2019--The “Portal Hypertension - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Portal Hypertension - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Portal Hypertension development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

The report provides a snapshot of the pipeline development for the Portal Hypertension The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Portal Hypertension The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Portal Hypertension The report also covers the dormant and discontinued pipeline projects related to Portal Hypertension

Reasons to Buy

Establish comprehensive understanding of the pipeline activity across this Portal Hypertension to formulate effective R&D strategies Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Portal Hypertension therapeutics Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Companies Mentioned

Conatus Pharmaceuticals Inc. Galectin Therapeutics Gilead Sciences Intercept Pharmaceuticals LinXis B.V. Ono Pharmaceutical Co.

Topics Covered

1. Report Introduction

2. Portal Hypertension Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Portal Hypertension

4. Comparative Analysis

5. Products in Clinical Stage

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

Product Description Research and Development Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/f4fv7t/portal?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190215005246/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/15/2019 08:09 AM/DISC: 02/15/2019 08:09 AM

http://www.businesswire.com/news/home/20190215005246/en